- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kashyap Patel, MD, Highlights the Struggles of Using Pegfilgrastim Biosimilars During the Pandemic
As COVID-19 cases continue to rise in many states, Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, provides insight into how biosimilar pegfilgrastims can help reduce costs; however, not all payers are on board.
Increasing the use of biosimilar pegfilgrastims can save patients and practices money as COVID-19 cases continue to surge; however, some payers are still preventing providers from utilizing them, according to Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Transcript:
How is the resurgence of the pandemic in South Carolina affecting your pegfilgrastim prescribing habits?
Patel: We are going to increase use of pegfilgrastim more and more and more. I had a pretty long email chain of a literal argument with one big payer saying that you cannot afford to overlook patient safety at the cost of saving money. And I hate to say this, but a couple of third party pathway companies still have not updated their guidelines, even though NCCN [National Comprehensive Cancer Network], ASCO [American Society for Clinical Oncology], and all the other bodies have recommended that, even for patients who are getting a chemotherapy regimen that carries intermediate risk of neutropenia during the pandemic, they recommend considering use of pegfilgrastim. And, in particular for our area, I think I would look at biosimilar pegfilgrastim, simply because this would be less expensive. But some payers are still giving us a hard time, and what they don't realize is that I'm trying to minimize my workflow interruption and optimize the efficiency. It's just been challenging, but we'll do our best to sustain and see where we go.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
